Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 166 | 3,378 | 2,640 | 3,543 | 11,063 |
| Marketable Securities | 47 | 35 | 40 | 3,583 | 39 |
| Receivables | 565 | 989 | 236 | 255 | 310 |
| TOTAL | $778 | $4,402 | $2,916 | $7,381 | $11,412 |
| Non-Current Assets | |||||
| PPE Net | 58 | 66 | 85 | 77 | 19 |
| Investments And Advances | 22 | 23 | 22 | 23 | 0 |
| Other Non-Current Assets | 170 | 84 | 162 | 229 | 0 |
| TOTAL | $250 | $173 | $269 | $329 | $19 |
| Total Assets | $1,028 | $4,575 | $3,185 | $7,710 | $11,431 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,516 | 1,992 | 3,459 | 1,726 | 597 |
| TOTAL | $2,516 | $1,992 | $3,459 | $1,726 | $597 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 1,412 | 218 | 1,828 |
| TOTAL | $72 | $N/A | $1,485 | $365 | $1,828 |
| Total Liabilities | $2,588 | $1,992 | $4,944 | $2,091 | $2,425 |
| Shareholders' Equity | |||||
| Retained earnings | -47,785 | -36,660 | -26,121 | -20,786 | -8,446 |
| TOTAL | $-1,560 | $2,583 | $-1,759 | $5,619 | $9,006 |
| Total Liabilities And Equity | $1,028 | $4,575 | $3,185 | $7,710 | $11,431 |